This article provides an overview and guidance on managing the disagreements that occur between the interpretation of medical images performed by investigators and those performed by blinded independent reviewers (BICR) in trials that involve imaging biomarkers.
Visit calyx.ai for more information.
About Calyx
Through innovative eClinical solutions and services, Calyx turns the uncertain into the reliable, helping bring new medical treatments to market faster. With deep expertise in clinical development and more than 25 years of supporting trial sponsors and clinical research organizations (CROs), Calyx harnesses that intelligence and activates its potential to solve complex problems, deliver fast insights, and get new drugs to market every day.
Medical Imaging | IRT | CTMS | EDC | RIM
Take your trials further, faster at calyx.ai, LinkedIn, Twitter, or Facebook.
Media Contact:
Christine Tobin | Christine.Tobin@calyx.ai |+1 412-628-8598
